Clinical Trial

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-10-24; most recent amendment 2026-04-07.
Status change: Recruiting → Active, Not Recruiting 2026-04-07
Status change: Not Yet Recruiting → Recruiting 2022-11-18
Trial Details
NCT Number NCT05595460
Lead Sponsor RayzeBio, Inc.
Conditions SCLC,Extensive Stage
Enrollment 21 participants
Start Date 2022-10-10
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-13